Reagent sensitivity for DOAC testing varies significantly between drug-spiked samples and patient samples, requiring reassessment of early laboratory recommendations.
Laboratory testing recommendations for DOACs must account for differences in reagent sensitivity between drug-spiked plasma and actual patient samples to prevent false-positive and false-negative results.
The introduction of direct oral anticoagulant (DOAC) therapy into clinical use in the past 5 years has had significant impact on the clinical laboratory. Clinicians' desire to determine plasma drug presence or measure drug concentration, and more recent observations regarding the limitations and utility of coagulation testing in the setting of DOAC treatment, suggest that early published recommendations regarding laboratory testing should be reassessed. These initial recommendations, furthermore, were often based on drug-spiked plasma studies, rather than samples from patients receiving DOAC therapy. We have demonstrated that reagent sensitivity varies significantly whether drug-spiked samples or samples from DOAC-treated patients are tested. Data from drug-enriched samples must therefore be interpreted with caution or be used as a guide only. We present laboratory assays that can be used to determine drug presence and to measure drug concentration, and provide recommended testing algorithms. As DOAC therapy may significantly impact on specialty coagulation assays, we review those tests with the potential to give false-positive and false-negative results.
Gosselin et al. (Thu,) conducted a review in Direct oral anticoagulant (DOAC) therapy. Direct oral anticoagulant (DOAC) testing was evaluated. Reagent sensitivity for DOAC testing varies significantly between drug-spiked samples and patient samples, requiring reassessment of early laboratory recommendations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: